Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-19T23:14:59.768Z Has data issue: false hasContentIssue false

Chapter 16 - Imaging in medication-induced parkinsonism

Published online by Cambridge University Press:  05 July 2015

By
Danna Jennings
Edited by
Joseph H. Friedman
Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Medication-Induced Movement Disorders , pp. 168 - 176
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barbosa, M, Caramelli, P, Maia, D, Cunningham, M, Guerra, H, Lima-Costa, M, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord. 2006;21:800–8.CrossRefGoogle ScholarPubMed
Benito-Leon, J, Bermejo-Paraja, F, Morales-Gonzales, J, Porta-Etessam, J, Trincado, R, Vega, S, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004;62:734–41.CrossRefGoogle ScholarPubMed
Stephen, P, Williamson, J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082–10–83.Google ScholarPubMed
Hardie, R, Lees, A. Neuroleptic-induced Parkinson’s syndrome: clincal features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51:850–4.CrossRefGoogle Scholar
Volkow, N, Ding, Y, Fowler, J, Wang, G, Logan, J, Gatley, S, et al. Evaluation of the human brain dopamine system with PET. J Nucl Med. 1996;37:1242–56.Google ScholarPubMed
Mutch, W, Strudwick, A, Roy, S, Downie, A. Parkinson’s disease: disability, review and management. Br Med J. 1986;13(293):675–7.Google Scholar
Esper, C, Factor, S. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord. 2007;23:401–4.Google Scholar
Corrigan, P, Liberman, R, Engel, J. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry. 1990;41:1203–11.Google ScholarPubMed
Jibson, M, Tandon, R. New atypical antipsychotic medications. J Psychiatry Res. 1998;32:215–28.CrossRefGoogle ScholarPubMed
Melamed, E, Achiron, A, Shapira, A, Davidovicz, S. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol. 1991;14:273–8.CrossRefGoogle ScholarPubMed
Goetz, C. Drug-induced parkinsonism and idiopathic Parkinson’s disease. Arch Neurol. 1983;40:325–6.CrossRefGoogle ScholarPubMed
Rajput, A, Rozdilsky, B, Hornykiewicz, O, et al. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol. 1982;39:644–6.CrossRefGoogle ScholarPubMed
Hambye, A, Vervat, A, Dethy, S. FP-CIT SPECT in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: a study with follow-up. Nucl Med Comm. 2010;31:583–89.CrossRefGoogle ScholarPubMed
Tinazzi, M, Antonini, A, Bovi, T, et al. Clinical and [123I] FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol. 2009;256:910–15.CrossRefGoogle ScholarPubMed
Lopez-Sendon, J, Mena, M, deYebenes, J. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging. 2012;29:105–18.CrossRefGoogle ScholarPubMed
Bondon-Guitton, E, Perez-Lloret, S, Bagheri, H, Brefel, C, Rascol, O, Monstrastruc, J. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226–31.CrossRefGoogle Scholar
Chakos, M, Mayerhoff, D, Loebel, A, Alvir, J, Lieberman, J. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharm Bull. 1992;28:81–6.Google ScholarPubMed
Korczyn, A, Goldberg, G. Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry. 1976;39:866–9.CrossRefGoogle ScholarPubMed
Tinazzi, M, Cipriani, A, Matinella, A, Cannas, A, Solla, P, Nicoletti, A, et al. [18F]FP-CIT single photon emission computed tomography findings in drug-induced parkinsonism. Schizophrenia Research. 2012;139:40–5.CrossRefGoogle Scholar
Burn, D, Brooks, D. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology. 1993;43:552–6.CrossRefGoogle ScholarPubMed
Farde, L, Wiesel, F, Halldin, C, Sedvall, G. D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45:71–6.CrossRefGoogle ScholarPubMed
Marek, K, Seibyl, J, Zoghbi, S, et al. [123I]b-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology. 1996;46:231–7.CrossRefGoogle Scholar
Morrish, P, Sawle, G, Brooks, D. Clinical and [18 F]Dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1995;59:597–600.CrossRefGoogle ScholarPubMed
Benamer, H, Patterson, J, Grosset, D, Booij, J, de Bruin, K, van Royen, E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Jennings, D, JP, S, Oakes, D, S E, Murphy, J, Marek, K. [123I]beta-CIT and single-photon emission computed tomographic imaging vs. clinical evaluation in parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004;61(8):1224–9.CrossRefGoogle ScholarPubMed
Catafu, A, Tolosa, E. The impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004;1:1175–82.Google Scholar
Marshall, V, Renininger, C, Marquardt, M, Patterson, J, Hadley, D, Oertel, W, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009(24):4.Google Scholar
Marshall, V, Patterson, J, Hadley, D, Grosset, K, Grosset, D. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nuc Med Commun. 2006;27(12):933–7.CrossRefGoogle ScholarPubMed
Lavalaye, J, Linszen, D, Booij, J, Dingermans, P, Renerman, L, Habraken, J, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123I]FP-CIT SPECT. Schizopren Res. 2001;47:59–67.CrossRefGoogle ScholarPubMed
Tolosa, E, Coelho, M, Gallardo, M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord. 2003;18 Suppl 7:S28-S33.CrossRefGoogle ScholarPubMed
Romero, J, Padillo, A, FJB, H, MM, G, Extremera, B. Utility of transcranial sonography in the diagnosis of drug-induced parkinsonism: a prospective study. Eur J Neurol. 2013;20:1451–58.Google Scholar
Lorberboym, M, Treves, T, E M, Y L, Hellmann, M, Djaldetti, R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord. 2006;21(4):510–4.CrossRefGoogle ScholarPubMed
Tinazzi, M, Ottaviani, S, Isaias, I, Pasquin, I, Steinmayr, M, Vampini, C, et al. [18F]FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord. 2008;23(13):1825–9.CrossRefGoogle Scholar
Marsden, C, Jenner, P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med. 1980;10:55–72.CrossRefGoogle ScholarPubMed
Patterson, T, Schenk, J. Effects of acute and chronic systemic administration of some typical antipsychotic drugs on turnover of dopamine and potassium ion-induced release of dopamine in the striatum of the rat in vivo. Neuropsychopharmacology. 1991;30:943–52.Google ScholarPubMed
Diaz-Corrales, F, Sanz-Viedma, S, Garcia-Solis, D, Escobar-Delgado, T, Mir, P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2010;37:556–64.CrossRefGoogle ScholarPubMed
Laruelle, M, Abi-Dargham, A, Gil, R, D’Souza, C, Zoghbi, S, Baldwin, R, et al. SPECT measurements of dopamine transporters in schizophrenia. J Nucl Med. 1996;37:33.Google Scholar
Knable, M, Hyde, T, Herman, M, Carter, J, Bigelow, L, Kleinman, J. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry. 1994;36(12):827–35.CrossRefGoogle ScholarPubMed
Czudek, C, Reynolds, G. [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. J Neurol Transm. 1989; 77 (2–3): 227–30.CrossRefGoogle Scholar
Mateos, J, Lomena, F, Parellada, E, Font, M, Fernandez, E, Pavia, J, et al. Decreased striatal dopamine transporter binding assessed with [123I]FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology. 2005;181:401–6.CrossRefGoogle ScholarPubMed
Dresel, S, Mager, T, Rossmuller, B, Meisenzahl, E, Hahn, K, Moller, H, et al. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. Eur J Nucl Med 1999;26:862–8.CrossRefGoogle Scholar
Nordstrom, A, Nyberg, S, Olsson, H, Farde, L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry. 1998;55:283–4.CrossRefGoogle ScholarPubMed
Raedler, T, Knable, M, Lafargue, T, Urbina, R, Egan, M, Pickar, D, et al. In vivo determination of striatal dopamine D-2 receptor occupancy in patients treated with olanzapine. Psychiatry Res: Neuroimaging. 1999;90:81–90.CrossRefGoogle Scholar
Nyberg, S, Eriksson, B, Oxenstiema, G, Halldin, C, Farde, L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5HT-2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156:869–75.CrossRefGoogle Scholar
Nordstrom, A, Farde, L, Wiesel, F, Forslund, K, Halldin, C, Uppfeldt, G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effect: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227–35.CrossRefGoogle ScholarPubMed
Kapur, S, Zipursky, R, Remington, G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286–93.CrossRefGoogle ScholarPubMed
Heinz, A, Knable, M, Weinberger, D. Dopamine D2 receptor imaging and neuroleptic drug response. J Clin Psychiatry. 1996;57(Suppl 11):84–8.Google ScholarPubMed
de Haan, L, Maksmovic, I. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized on olanzapine or risperidone. Am J Psychiatry. 1999;157:1019–20.Google Scholar
Rascol, O. 123I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord. 2009;24(Suppl 2):S732–41.CrossRefGoogle ScholarPubMed
Lee, P, Kim, J, Shin, D, Yoon, S, Huh, K. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2006;77:372–4.Google ScholarPubMed
Lee, P, Yeo, S, Yong, S, Kim, Y. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2007;78:1250–2.CrossRefGoogle ScholarPubMed
Kim, J, Oh, Y, Kim, Y, Yang, D, Chung, Y, You, I, et al. Combined use of 123I-metaiodobenzlguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET predicts prognosis in drug-induced parkinsonism (DIP): A 2-year follow-up study. Arch Gerontol Geriat. 2013;56:124–8.CrossRefGoogle ScholarPubMed
Gaenslen, A, Unmuth, B, Godau, J, Liepelt, I, SiSanto, A, Schweitzer, K, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study. Lancet Neurol. 2008;7:417–24.CrossRefGoogle ScholarPubMed
Berg, D, Roggendorf, W, Schroder, U, et al. Echogenicity of the substantia nigra: association with increased iron contect and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002;59:999–1005.CrossRefGoogle Scholar
Berg, D, Siefker, C, Becker, G. Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol. 2001;248:684–89.CrossRefGoogle ScholarPubMed
Walter, U, Wittstock, M, Benecke, R, Dressler, D. Sustantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson’s disease. J Neural Transm. 2002;109:191–96.CrossRefGoogle Scholar
Becker, G, Sueufert, J, Bogdahn, U, Reichmann, H, Reiners, K. Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real time sonography. Neurology. 1995;45:182–84.CrossRefGoogle ScholarPubMed
Tsai, C, Wu, R, Huang, Y, et al. Transcranial color-coded sonography helps differentiation of Parkinson’s disease and vascular parkinsonism. J Neurol. 2007;254:501–7.CrossRefGoogle ScholarPubMed
Bouwmans, A, Vlaar, A, Mess, W, Kessels, A, Weber, W. Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson’s disease: prospective cohort study in 196 patients. BMJ Open. 2013;3:e002613 doi:10.1136.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×